618 related articles for article (PubMed ID: 7686889)
21. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.
Azuma M; Cayabyab M; Buck D; Phillips JH; Lanier LL
J Exp Med; 1992 Feb; 175(2):353-60. PubMed ID: 1370679
[TBL] [Abstract][Full Text] [Related]
22. Targeting of "T" lymphocytes against human hepatoma cells by a bispecific monoclonal antibody: role of different lymphocyte subsets.
Chen Q; Sun P; Prigione I; Xie H; Ferrini S
Tumori; 1992 Apr; 78(2):79-86. PubMed ID: 1326141
[TBL] [Abstract][Full Text] [Related]
23. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones.
Ferrini S; Prigione I; Miotti S; Ciccone E; Cantoni C; Chen Q; Colnaghi MI; Moretta L
Int J Cancer; 1991 May; 48(2):227-33. PubMed ID: 1826900
[TBL] [Abstract][Full Text] [Related]
24. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
25. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
Clin Exp Immunol; 1997 May; 108(2):352-7. PubMed ID: 9158110
[TBL] [Abstract][Full Text] [Related]
26. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
Haagen IA; van de Griend R; Clark M; Geerars A; Bast B; de Gast B
Clin Exp Immunol; 1992 Dec; 90(3):368-75. PubMed ID: 1281055
[TBL] [Abstract][Full Text] [Related]
27. Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules.
Ferrini S; Cambiaggi A; Cantoni C; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
Int J Cancer Suppl; 1992; 7():15-8. PubMed ID: 1428398
[TBL] [Abstract][Full Text] [Related]
28. The anti-T cell monoclonal antibody 9.3 (anti-CD28) provides a helper signal and bypasses the need for accessory cells in T cell activation with immobilized anti-CD3 and mitogens.
Baroja ML; Lorre K; Van Vaeck F; Ceuppens JL
Cell Immunol; 1989 Apr; 120(1):205-17. PubMed ID: 2539266
[TBL] [Abstract][Full Text] [Related]
29. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
Gargett T; Brown MP
Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
[TBL] [Abstract][Full Text] [Related]
30. Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells.
Ferrini S; Cambiaggi A; Sforzini S; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
Cancer Detect Prev; 1993; 17(2):295-300. PubMed ID: 8402715
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-1-independent activation of human T lymphocytes stimulated by anti-CD3 and a Hodgkin's disease cell line with accessory cell activity.
Ellis TM; McMannis JD; Chua AO; Gubler U; Fisher RI
Cell Immunol; 1988 Oct; 116(2):352-66. PubMed ID: 2972387
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous cross-linking of CD6 and CD28 induces cell proliferation in resting T cells.
Osorio LM; Rottenberg M; Jondal M; Chow SC
Immunology; 1998 Mar; 93(3):358-65. PubMed ID: 9640246
[TBL] [Abstract][Full Text] [Related]
33. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.
Gimmi CD; Freeman GJ; Gribben JG; Sugita K; Freedman AS; Morimoto C; Nadler LM
Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6575-9. PubMed ID: 1650475
[TBL] [Abstract][Full Text] [Related]
34. Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway.
Reinhold MI; Lindberg FP; Kersh GJ; Allen PM; Brown EJ
J Exp Med; 1997 Jan; 185(1):1-11. PubMed ID: 8996237
[TBL] [Abstract][Full Text] [Related]
35. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
36. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28.
Kroesen BJ; Bakker A; van Lier RA; The HT; de Leij L
Cancer Res; 1995 Oct; 55(19):4409-15. PubMed ID: 7545540
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies to common epitopes of the human alpha/beta T-cell receptor preferentially activate CD45RA+ T-cells.
Schwinzer R; Schlitt HJ; Wonigeit K
Cell Immunol; 1992 Mar; 140(1):31-41. PubMed ID: 1531453
[TBL] [Abstract][Full Text] [Related]
38. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
39. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H
J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771
[TBL] [Abstract][Full Text] [Related]
40. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
